FDA approves hedgehog pathway inhibitor for locally advanced BCC
Sonidegib, a hedgehog pathway inhibitor, has been approved for treating patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy, the Food and Drug Administration <a...
Source: Skin and Allergy News - Category: Dermatology Source Type: news
More News: Allergy | Allergy & Immunology | Basal Cell Carcinoma | Cancer & Oncology | Carcinoma | Dermatology | Food and Drug Administration (FDA) | Radiation Therapy | Skin | Skin Cancer